Valeur Intrinsèque du S&P et Nasdaq Contactez-nous
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Retour aux actions

Atea Pharmaceuticals, Inc. AVIR NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$6.88
+17%

Il y a eu 50 transactions d'initiés récentes enregistrées pour Atea Pharmaceuticals, Inc. (AVIR), dont 17 achats et 31 ventes. Le total des achats d'initiés s'élève à $1.21M et le total des ventes d'initiés à $2.16M.

Les initiés notables ayant une activité récente comprennent Corcoran Andrea, Sommadossi Jean-pierre, Foster Wayne. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.

Transactions d'Initiés — AVIR

Date Nom Rôle Type de Transaction Actions Prix Moyen Valeur Actions détenues
2026-03-11 Corcoran Andrea See Remarks Exercice d'Options 60,000 $1.24 $74.4K -
2026-02-03 Sommadossi Jean-pierre President, CEO, and Chairman Exercice d'Options (Vente) 300,000 $1.24 $372K -
2026-01-31 Sommadossi Jean-pierre President, CEO, and Chairman Exercice d'Options (Vente) 99,517 - - -
2026-01-31 Corcoran Andrea See Remarks Exercice d'Options (Vente) 10,500 - - -
2026-01-31 Foster Wayne EVP, Chief Accounting Officer Exercice d'Options (Vente) 8,000 - - -
2026-01-31 Horga Maria Arantxa Chief Medical Officer Exercice d'Options (Vente) 9,750 - - -
2026-01-31 Vavricka John Chief Commercial Officer Exercice d'Options (Vente) 8,750 - - -
2026-01-31 Hammond Janet Mj Chief Development Officer Exercice d'Options (Vente) 11,250 - - -
2025-06-20 Berger Franklin M Director Exercice d'Options (Vente) 29,600 - - -
2025-06-20 Duncan Barbara Gayle Director Exercice d'Options (Vente) 29,600 - - -
2025-06-20 Polsky Bruce Director Exercice d'Options (Vente) 29,600 - - -
2025-06-20 Murphy Polly A. Director Exercice d'Options (Vente) 29,600 - - -
2025-06-20 Lucidi Bruno Director Exercice d'Options (Vente) 29,600 - - -
2025-06-20 Adams Jerome M. Director Exercice d'Options (Vente) 29,600 - - -
2025-06-20 Berman Howard Officer Inconnu - - - -
2025-06-20 Berman Howard Director Attribution de RSU 164,800 $3.25 $535.6K 164,800
2025-02-20 Kirsch Arthur S Director Inconnu - - - 10,000
2025-02-20 Kirsch Arthur S Director Attribution de RSU 164,800 $3.14 $517.47K 164,800
2025-01-31 Sommadossi Jean-pierre President, CEO, and Chairman Attribution de RSU 99,518 - - 99,518
2025-01-31 Corcoran Andrea See Remarks Attribution de RSU 10,500 - - 10,500
2025-01-31 Foster Wayne EVP, Chief Accounting Officer Attribution de RSU 8,000 - - 8,000
2025-01-31 Horga Maria Arantxa Chief Medical Officer Attribution de RSU 9,750 - - 9,750
2025-01-31 Vavricka John Chief Commercial Officer Attribution de RSU 8,750 - - 8,750
2025-01-31 Hammond Janet Mj Chief Development Officer Attribution de RSU 11,250 - - 11,250
2025-01-16 Berger Franklin M Director Vente Informative 10,000 $3.36 $33.61K 476,897
2025-01-16 Berger Franklin M Director Achat Informatif 10,000 $3.36 $33.61K 476,897
2025-01-15 Berger Franklin M Director Vente Informative 15,000 $3.19 $47.88K 466,897
2025-01-15 Berger Franklin M Director Achat Informatif 15,000 $3.19 $47.88K 466,897
2024-12-10 Berger Franklin M Director Vente Informative 359,606 $2.85 $1.02M 451,897
2024-09-19 Sommadossi Jean-pierre President, CEO, and Chairman Vente Informative 1,841 $4.00 $7.37K 5,866,025
2024-09-18 Sommadossi Jean-pierre President, CEO, and Chairman Vente Informative 22,187 $4.03 $89.47K 5,867,866
2024-09-17 Sommadossi Jean-pierre President, CEO, and Chairman Vente Informative 33,941 $4.05 $137.32K 5,890,053
2024-06-21 Berger Franklin M Director Attribution de RSU 29,600 - - 29,600
2024-06-21 Duncan Barbara Gayle Director Attribution de RSU 29,600 - - 29,600
2024-06-21 Polsky Bruce Director Attribution de RSU 29,600 - - 29,600
2024-06-21 Murphy Polly A. Director Attribution de RSU 29,600 - - 29,600
2024-06-21 Lucidi Bruno Director Attribution de RSU 29,600 - - 29,600
2024-06-21 Adams Jerome M. Director Attribution de RSU 29,600 - - 29,600
2024-06-20 Polsky Bruce Director Vente Informative 17,544 $3.49 $61.14K 65,606
2024-06-16 Berger Franklin M Director Exercice d'Options (Vente) 33,150 - - -
2024-06-16 Duncan Barbara Gayle Director Exercice d'Options (Vente) 33,150 - - -
2024-06-16 Polsky Bruce Director Exercice d'Options (Vente) 33,150 - - -
2024-06-16 Murphy Polly A. Director Exercice d'Options (Vente) 33,150 - - -
2024-06-16 Lucidi Bruno Director Exercice d'Options (Vente) 33,150 - - -
2024-06-16 Adams Jerome M. Director Exercice d'Options (Vente) 33,150 - - -
2024-06-05 Sommadossi Jean-pierre President, CEO, and Chairman Vente Informative 1,006 $4.00 $4.02K 5,923,994
2024-02-01 Sommadossi Jean-pierre President, CEO, and Chairman Vente Informative 56,910 $3.85 $218.82K 116,557
2024-02-01 Corcoran Andrea See Remarks Vente Informative 15,843 $3.84 $60.91K 670,208
2024-02-01 Foster Wayne EVP, Chief Accounting Officer Vente Informative 12,477 $3.84 $47.9K 20,857
2024-02-01 Horga Maria Arantxa Chief Medical Officer Vente Informative 15,870 $3.84 $60.96K 25,664
■ Informatif — transaction sur marché ouvert (la plus significative) ■ Non informatif (achat) — récompense, exercice d'option, conversion ■ Non informatif (vente) — retenue fiscale, vente à l'acquisition ■ Neutre — don, fiducie, expiration

Les autres consultent aussi

IMMX
IMMX
Immix Biopharma, Inc.
$10.04
+1.93%
 FRLN
FRLN
Freeline Therapeutics Holdings plc
$6.49
+0.15%
 ELEV
ELEV
Elevation Oncology, Inc.
$0.37
-2.12%
 AVRO
AVRO
AVROBIO, Inc.
$1.40
-1.41%
 CNSP
CNSP
CNS Pharmaceuticals, Inc.
$2.75
+4.17%
 ENVB
ENVB
Enveric Biosciences, Inc.
$2.03
+4.10%
 CWBR
CWBR
CohBar, Inc.
$0.41
+0.00%
 HEPA
HEPA
Hepion Pharmaceuticals, Inc.
$0.04
-19.58%
Contactez-nous
🎓
SharesGrow Académie
Apprenez à calculer la Valeur Intrinsèque et trouver des actions sous-évaluées.
Sessions hebdomadaires en direct
📧 [email protected]
📞 +65 8912 8000
Envoyez-nous un message